BioClin is a supplier of contract bio-analysis and analytical research and development, with advanced analytical services including liquid chromatography-tandem mass spectrometry (LC/MS/MS)
Intertek has acquired BioClin Research Laboratories (BioClin).
BioClin has been serving the local and international pharmaceutical, medical device and drug delivery industry for more than five years.
Located in Athlone and with 20 staff, BioClin is highly regarded for its technical expertise, rigorous compliance programmes, and outstanding customer service.
The laboratory is Good Laboratory Practice (GLP) certified and is a current Good Manufacturing Practice (cGMP) facility that has been inspected by the IMB.
The acquisition advances Intertek's strategic growth in expert support services to the global pharmaceutical, medical device and drug delivery industry.
BioClin will operate in Intertek's pharmaceutical services group within its Analytical Services division.
Andrew Swift, executive vice president of Intertek's Analytical Services Division, comments: "BioClin has a strong reputation in the industry.
"Acquiring BioClin further expands Intertek's support globally to the pharmaceutical and related sectors for outsourced R+D and analytical services".
John Conti-Ramsden, global director of Intertek's pharmaceutical services, said: "BioClin further extends our offering in Europe as well as our global platform supporting pharmaceutical R+D and manufacturing in key locations.
"Intertek already provides a wide range of testing services to pharmaceutical clients from its laboratories in the United Kingdom, USA, India and Australia".
Mary Burke, managing director, and Brian McKenna, scientific director of BioClin commented jointly: "Joining Intertek will allow BioClin's local and international clients to gain from Intertek's global network and surrounding experts and facilities give.
"It also gives BioClin an exciting opportunity to provide our expert services to a wider network of new international clients and markets."
